May. 14 at 9:15 PM
$CRDF “In April, we had a successful End‑of‑Phase 2 meeting with the FDA and aligned on the key design elements for our Phase 3
registrational trial. We plan to share additional Phase 3 details and our regulatory strategy in mid-2026. At the upcoming ASCO
Annual Meeting, we will present updated CRDF-004 data, which we believe will provide further insight into onvansertib's
potential in the first-line RAS-mutated metastatic colorectal cancer (mCRC) setting. In parallel, we continue to strengthen the
scientific foundation of our PLK1 inhibition strategy, supported by new preclinical data evaluating combination use with an
antibody-drug conjugate, as well as ongoing single-agent and combination investigator-initiated studies across multiple cancer
settings. With strong clinical momentum, we remain focused on disciplined execution throughout the year.
https://investors.cardiffoncology.com/static-files/35b17494-0ef1-4084-b3c9-d7a134b4f4dd
